Masková Jana, Komárková Jana, Kivánek Jirí, Danes Jan, Slavíková Marcela
Department of Radiology, University Hospital, U nemocnice 2, Prague 2, 12800, Czech Republic.
Cardiovasc Intervent Radiol. 2003 Jan-Feb;26(1):27-30. doi: 10.1007/s00270-002-1960-7. Epub 2002 Dec 20.
To report our experience and results with the endovascular treatment of central vein stenoses and occlusions in hemodialysis patients.
Between October 1999 and August 2001 (22 months) we performed 22 interventional procedures in 14 hemodialysis patients (8 women, 6 men) ranging in age from 38 to 87 years (mean 76 years). The indication for intervention was stenosis (n = 10) or occlusion (n = 4) of a central vein in the upper arm used for dialysis in patients with arm swelling and/or shunt malfunction. All patients had a previous history of subclavian vein cannulation. There were six percutaneous transluminal angioplasties (PTAs) and eight primary stent placements and eight repeat interventions. Seven were for restenoses and one for early occlusion, with two secondary stent placements and six PTA of in-stent stenoses. In two patients a second stent was implanted. The mean follow-up was 8.5 months (range 1-19 months). All stents were self-expandable with diameters ranging from 9 to 16 mm.
All but one of the procedures was technically successful (95%, n = 21). The patient with an unsuccessful procedure died 1 month after the procedure, but the death was not procedure-related. During follow-up three patients died with a patent shunt and central vein, none of them in connection with the procedure. No complication occurred during the interventional procedures. One patient was lost to follow-up. The primary patency rate at 12 months was 43%, with a primary assisted patency rate of 83% and a secondary patency rate of 100% (n = 6).
Central vein stenoses and occlusions are associated with previous subclavian vein cannulation. They are a serious problem in hemodialysis patients with a shunt on the same arm. Endovascular treatment is a suitable option for these patients.
报告我们对血液透析患者中心静脉狭窄和闭塞进行血管内治疗的经验及结果。
在1999年10月至2001年8月(22个月)期间,我们对14例血液透析患者(8例女性,6例男性)进行了22次介入手术,患者年龄在38至87岁之间(平均76岁)。介入治疗的指征为用于透析的上臂中心静脉狭窄(n = 10)或闭塞(n = 4),伴有手臂肿胀和/或分流功能障碍。所有患者既往均有锁骨下静脉插管史。其中有6例经皮腔内血管成形术(PTA)、8例初次支架置入及8例再次介入治疗。7例为再狭窄,1例为早期闭塞,其中2例为二次支架置入,6例为支架内狭窄的PTA。2例患者植入了第二个支架。平均随访时间为8.5个月(范围1 - 19个月)。所有支架均为自膨式,直径范围为9至16毫米。
除1例手术外,其余所有手术在技术上均获成功(95%,n = 21)。手术未成功的患者在术后1个月死亡,但死亡与手术无关。随访期间,3例患者在分流和中心静脉通畅的情况下死亡,均与手术无关。介入手术期间未发生并发症。1例患者失访。12个月时的初次通畅率为43%,初次辅助通畅率为83%,二次通畅率为100%(n = 6)。
中心静脉狭窄和闭塞与既往锁骨下静脉插管有关。对于同一手臂有分流的血液透析患者而言,这是一个严重问题。血管内治疗是这些患者的合适选择。